Loading...
Loading...
URGN| Name | Value |
|---|---|
| Revenues | 21.8M |
| Cost of Revenue | 2.2M |
| Gross Profit | 19.6M |
| Operating Expense | 45.5M |
| Operating I/L | -25.8M |
| Other Income/Expense | -7.5M |
| Interest Income | 1.7M |
| Pretax | -33.4M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -33.4M |
UroGen Pharma Ltd. is a biotechnology company specializing in the development and commercialization of innovative solutions for specialty cancers and urothelial diseases. The company's primary focus is on advancing its lead product candidate, UGN-102, through Phase III clinical trials for the treatment of various forms of non-muscle invasive urothelial cancer. Additionally, UroGen Pharma offers RTGel, a hydrogel technology designed to enhance the therapeutic profiles of existing drugs, and has a strategic research collaboration with MD Anderson to advance investigational treatments for high-grade bladder cancer.
